
    
      The prospective registry study and retrospective data collection study is planned to assess
      the efficacy and safety of Vivigen Cellular Bone Matrix (Vivigen) in orthopaedic trauma
      patients who require bone grafting in the acute, delayed, non-union fracture as well as use
      in fusion procedure settings.

      Patients will be assessed at hospital discharge, 6 weeks, 3 months, 6 months, 12 months and
      24 months after treatment of a traumatic fracture with a bone graft.
    
  